-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Natural Killer Cell-Based Immunotherapy

Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Clinical Trials, Clinical Practice (Health Services and Quality), Workforce
Wednesday, December 15, 2021: 5:00 PM-6:00 PM
(VIRTUAL PROGRAM)
Please view the recorded poster presentations prior to attending this virtual session:

This poster walk would aim to highlight recent advance in use of natural killer (NK) cells for improved cancer therapies. NK cell-based therapies are now being pursued from many sources including cord blood, peripheral blood and iPSCs. There are also agents (Bikes, Trikes, cytokines such as IL15, etc) to stimulate endogenous NK cells that are being developed. This poster walk would highlight both pre-clinical and clinical studies that show the progress in this field.

The following abstracts will be featured in this session:

iPSC-Derived Natural Killer Cells and Macrophages Synergistically Kill Acute Myeloid Leukemia Blasts, Benjamin Goldenson

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma, Krish Patel

Using NK-Derived Exosomes to Treat Leukemia, Aladin Samara

Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30+ Malignancies, Joachim Koch

FLT3 OR CD33 NOT EMCN Logic Gated CAR-NK Cell Therapy (SENTI-202) for Precise Targeting of AML, Brian Garrison

See more of: ASH Poster Walks